Department of Pathology, Microbiology, and Immunology


Holly Algood, Ph.D.


Assistant Professor
Dept. of Medicine – Infectious Diseases

Dept. of Pathology, Microbiology and Immunology

  Contact Information

  Office Location:
A2210 MCN
Phone: 615-343-9242
Campus Mail address:
AA-2200 MCN

US Mailing address:
Vanderbilt University School of Medicine
Dept of Medicine
AA-2200 MCN
1161 21st Ave. South
Nashville, TN 37232






PhD, University of Pittsburgh
BS, Mt Union College



Research Keywords



Helicobacter pylori, inflammation, T lymphocytes, cytokines, bacterial pathogenesis, Th17, bacterial response, oxidative stress, host-pathogen interactions



Research Description



Projects in Dr. Algood's lab focus on pathogen - host interactions in chronic infections and during chronic inflammation. Her main model system is Helicobacter pylori infection. Helicobacter pylori is a Gram-negative pathogen which can chronically colonize the human stomach and lead to adverse disease outcomes such as peptic ulcers or gastric cancer. Her projects investigate how T cell cytokines influence gastric epithelial cells responding to infection but also even more broadly how T cell cytokines activate other cells to protect the epithelial cells and the mucosal barrier they maintain. Dr. Algood's research utilizes H. pylori as a model mucosal pathogen, but her long-term research interests lie in understanding the balance between the mucosal immune responses, pathogens, and normal flora. While immune responses may be necessary to control bacterial colonization at the mucosal surfaces, the immune response must also be well controlled to maintain epithelial cell integrity and to control infiltration of other potentially damaging immune cells. Th17-driven immune responses have been implicated in pro-inflammatory activity and induction of chronic inflammation; she would like to better understand how the Th17 response is balanced. Moreover, since the inflammatory/immune response is not sufficient to clear the infection, Dr. Algood's laboratory is beginning studies to investigate how the bacteria persist while combated with the stresses of the immune response.






Carbo, A, Olivares-Villagomez, D, Hontecillas, R, Bassaganya-Riera, J, Chaturvedi, R, Piazuelo, MB, Delgado, A, Washington, MK, Wilson, KT, Algood, HM. Systems modeling of the role of interleukin-21 in the maintenance of effector CD4+ T cell responses during chronic Helicobacter pylori infection. MBio, 5(4), e01243-14, 2014

Radin, JN, Gonzolez-Rivera, C, Frick-Cheng, AE, Sheng, J, Gaddy, JA, Rubin, DH, Algood, HM, McClain, MS, Cover, TL. Role of connexin 43 in Helicobacter pylori VacA-induced cell death. Infect Immun, 82(1), 423-32, 2014

Gaddy, JA, Radin, JN, Loh, JT, Zhang, F, Washington, MK, Peek, RM, Algood, HM, Cover, TL. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Infect Immun, 81(6), 2258-67, 2013

Radin, JN, Gaddy, JA, Gonzalez-Rivera, C, Loh, JT, Algood, HM, Cover, TL. Flagellar Localization of a Helicobacter pylori Autotransporter Protein. MBio, 4(2), 2013

Horvath, DJ, Radin, JN, Cho, SH, Washington, MK, Algood, HM. The Interleukin-17 Receptor B subunit ss essential for the Th2 response to Helicobacter pylori, but not for control of bacterial burden. PLoS One, 8(3), e60363, 2013

Horvath, DJ, Washington, MK, Cope, VA, Algood, HM. IL-23 contributes to control of chronic Helicobacter pylori infection and the development of T Helper responses in a mouse model. Front Immunol, 3, 56, 2012

Gonzalez-Rivera, C, Algood, HM, Radin, JN, McClain, MS, Cover, TL. The intermediate region of Helicobacter pylori VacA is a determinant of toxin potency in a Jurkat T cell assay. Infect Immun, 80(8), 2578-88, 2012

Olivares-Villagomez, D, Algood, HM, Singh, K, Parekh, VV, Ryan, KE, Piazuelo, MB, Wilson, KT, Van Kaer, L. Intestinal epithelial cells modulate CD4 T cell responses via the thymus leukemia antigen. J Immunol, 187(8), 4051-60, 2011

Goettel, JA, Scott Algood, HM, Olivares-Villagomez, D, Washington, MK, Chaturvedi, R, Wilson, KT, Van Kaer, L, Polk, DB. KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-gamma production. Gastroenterology, 140(1), 265-74, 2011

Asim, M, Chaturvedi, R, Hoge, S, Lewis, ND, Singh, K, Barry, DP, Algood, HS, de Sablet, T, Gobert, AP, Wilson, KT. Helicobacter pylori induces ERK-dependent formation of a phospho-c-Fos c-Jun activator protein-1 complex that causes apoptosis in macrophages. J Biol Chem, 285(26), 20343-57, 2010

Ivie, SE, McClain, MS, Algood, HM, Lacy, DB, Cover, TL. Analysis of a beta-helical region in the p55 domain of Helicobacter pylori vacuolating toxin. BMC Microbiol, 10, 60, 2010

Algood, HM, Allen, SS, Washington, MK, Peek, RM, Miller, GG, Cover, TL. Regulation of gastric B cell recruitment is dependent on IL-17 receptor A signaling in a model of chronic bacterial infection. J Immunol, 183(9), 5837-46, 2009

Ivie, SE, McClain, MS, Torres, VJ, Algood, HM, Lacy, DB, Yang, R, Blanke, SR, Cover, TL. Helicobacter pylori VacA subdomain required for intracellular toxin activity and assembly of functional oligomeric complexes. Infect Immun, 76(7), 2843-51, 2008

Loh, JT, Torres, VJ, Algood, HM, McClain, MS, Cover, TL. Helicobacter pylori HopQ outer membrane protein attenuates bacterial adherence to gastric epithelial cells. FEMS Microbiol Lett, 289(1), 53-8, 2008

Chaturvedi, R, Asim, M, Lewis, ND, Algood, HM, Cover, TL, Kim, PY, Wilson, KT. L-arginine availability regulates inducible nitric oxide synthase-dependent host defense against Helicobacter pylori. Infect Immun, 75(9), 4305-15, 2007

Algood, HM, Torres, VJ, Unutmaz, D, Cover, TL. Resistance of primary murine CD4+ T cells to Helicobacter pylori vacuolating cytotoxin. Infect Immun, 75(1), 334-41, 2007

Algood, HM, Gallo-Romero, J, Wilson, KT, Peek, RM, Cover, TL. Host response to Helicobacter pylori infection before initiation of the adaptive immune response. FEMS Immunol Med Microbiol, 51(3), 577-86, 2007

Algood, HM, Cover, TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev, 19(4), 597-613, 2006

Algood, HM, Lin, PL, Flynn, JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis, 41 Suppl 3, S189-93, 2005

Algood, HM, Flynn, JL. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J Immunol, 173(5), 3287-96, 2004

Algood, HM, Lin, PL, Yankura, D, Jones, A, Chan, J, Flynn, JL. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol, 172(11), 6846-57, 2004

Algood, HM, Chan, J, Flynn, JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev, 14(6), 467-77, 2003

Scott, HM, Flynn, JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun, 70(11), 5946-54, 2002

Peters, W, Scott, HM, Chambers, HF, Flynn, JL, Charo, IF, Ernst, JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis

Mohan, VP, Scanga, CA, Yu, K, Scott, HM, Tanaka, KE, Tsang, E, Tsai, MM, Flynn, JL, Chan, J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun, 69(3), 1847-55, 2001